|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer |
| Sima Porten, MD, MPH |
| Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment. |
|
|
|
|
|
|
|
|
|
|
|
|
Adequate BCG Therapy for Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Analysis
|
|
José Daniel Subiela Henriquez, MD, PhD
|
| José Daniel Subiela Henriquez presented findings from his multicenter study on BCG therapy for very high-risk NMIBC. Dr. Subiela's research evaluates the effectiveness of BCG in a group where the European Association of Urology had recommended radical cystectomy due to high progression risks.
|
|
|
|
|
|
|
|
|
|
|
|
| AI-Based Assessment Tool for Predicting BCG Response in Bladder Cancer Patients |
Yair Lotan, MD
Ashish Kamat and Yair Lotan discuss an innovative AI-based assessment tool presented by Valar Labs, aimed at refining the management of BCG-unresponsive bladder cancer. Dr. Lotan discusses the tool's capability to enhance the precision of prognosis and treatment strategies by analyzing pathologic slides with AI to identify high-risk patients who might not respond well to BCG treatment. |
|
|
|
|
|
|
|
|
|
|
|
Novel Bladder Cancer Treatment: Mechanisms, Clinical Findings, and Implications
|
Patrick Soon-Shiong, MD
Ashish Kamat and Patrick Soon-Shiong explore the clinical development and FDA approval of Anktiva for bladder cancer. Dr. Soon-Shiong outlines the journey from initial studies in BCG-naive and BCG-unresponsive patients to approval.
|
|
|
|
|
|
|
|
|
|
|
| BCG Shortage: What’s on the Horizon to Replace? |
| Joshua J Meeks, MD, PhD |
| Josh Meeks addressed the ongoing BCG shortage for urothelial carcinoma treatment and explored potential alternatives. He discussed the challenges of BCG production and presented options such as gemcitabine + docetaxel, which shows promise as an effective substitute, and the potential use of immune checkpoint inhibitors and novel drug delivery systems like TARIS. |
|
|
|
|
|
| MoonRISe-1: Phase 3 Study of TAR-210, an Erdafitinib Intravesical Delivery System, Versus Intravesical Chemotherapy in Patients with Intermediate-Risk NMIBC with Susceptible FGFR Alterations
|
| Roger Li, MD
|
| Roger Li presented the MoonRISe-1 phase 3 study, comparing TAR-210, an intravesical erdafitinib delivery system, to intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer with FGFR alterations. TAR-210 aims to provide sustained erdafitinib delivery over 90 days while minimizing systemic toxicities.
|
|
|
|
|
|
|
|
|
|
|
| Predicting Response to Intravesical BCG in High-Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort |
| Yair Lotan, MD |
| Yair Lotan presented an AI-powered pathology assay designed to predict the response to intravesical BCG in high-risk non-muscle invasive bladder cancer. The assay outperformed traditional models, offering a rapid and accessible tool for clinicians to optimize treatment decisions, particularly in the context of BCG shortages and emerging alternative therapies. |
|
|
|
|
|
| N-803 plus BCG Complete Response Rate in NMIBC CIS: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032) |
| Patrick Soon-Shiong, MD |
| Patrick Soon-Shiong presented updated results from the QUILT 3.032 trial, which investigated N-803 (ANKTIVA®) combined with BCG in patients with BCG-unresponsive high-grade non-muscle invasive bladder cancer (NMIBC). The trial reported a complete response rate of 65% among 94 subjects, with the median duration of response being 26.6 months. |
|
|
|
|
|
Radical Cystectomy versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Beyond the Abstract
|
| Alexandre Zlotta, MD & Jason Efstathiou, MD |
| A multi-institutional study comparing radical cystectomy and trimodality therapy for muscle-invasive bladder cancer found no significant differences in oncological outcomes, such as disease-free survival, metastasis-free survival, and cancer-specific survival, between the two treatments. Despite TMT's effectiveness, 13% of patients required salvage cystectomy due to invasive recurrence, and 20% experienced non-invasive recurrences, emphasizing the need for lifelong cystoscopic surveillance. |
|
|
|
|
|
|
|
|
|
|
